-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharming Group's Joenja Approved In Japan As First Targeted Treatment For Activated PI3K Delta Syndrome In Patients Aged 4 Years And Older

Benzinga·03/24/2026 06:17:54
Listen to the news
  • First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
  • Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 years
  • First approval of Joenja covering children aged 4 to 11 with APDS